Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.
A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...
Microdosing Ozempic, a weight-loss drug, is gaining popularity, with users claiming benefits like reduced hunger and weight loss. Experts are cautious due to the lack of research, though some ...
Experts don’t all agree on such a use for the drugs. By Dani Blum A new study adds to mounting evidence showing that drugs like Ozempic don’t just treat diabetes — they can also prevent it.
As drugs like Ozempic and Wegovy keep flying off pharmacy shelves, more and more patients are ignoring manufacturers' and medical professionals' instructions by "microdosing" it. As the New York ...
Ozempic can help with blood sugar management, aid with significant weight loss, and perhaps even treat opioid use disorder. Now, there’s one more thing to add to the list: alcohol addiction. New ...
It seemed simple enough: She was charged a subscription fee and a fee for the medication she ordered, semaglutide, which is basically generic Ozempic. She quickly noticed her food cravings and ...
Weight loss drugs such as Ozempic and Wegovy are enormously popular for people with diabetes, obesity and cardiovascular risk. So, health professionals wondered: Could these drugs also be the key ...
Since Ozempic was approved by the Food and Drug Administration (FDA) in 2017, the medication (and other GLP-1 agonists like it) has become famous for helping people lose a significant amount of ...
The Biden administration is expanding coverage of anti-obesity drugs such as Ozempic and Wegovy for people with Medicare and Medicaid through a new proposal from the Department of Health and Human ...
Donald Trump's top pick to lead Medicare, the celebrity doctor Mehmet Oz, has at least one glaring conflict of interest: that he was sponsored by the company that makes Ozempic. Though a Novo ...